Everest Medicine license agreement extended to include South Korea

STOCKHOLM, March 14, 2022 /PRNewswire/ — Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the company has expanded its licensing agreement with Everest Medicines II Limited (HKG: 1952) (“Everest”) to expand the territory covered to include South Korea.

“We continue to have a fruitful and positive collaboration with Everest and we are delighted to have reached an agreement also around South Korea“said CEO Renée Aguiar-Lucander.

The extension entails an initial payment of $3 million to Calliditas as well as additional payments and royalties related to potential future approvals and commercialization of Nefecon in South Korea. Calliditas and Everest entered into a licensing agreement in 2019 to develop and commercialize Nefecon in Greater China and Singapore for chronic autoimmune kidney disease IgA nephropathy (IgAN).

For more information, please contact:

Mary GalayHead of International Relations, Calliditas

Phone. : +44 79 55 12 98 45, email: [email protected]

The information was sent for publication, through the contact persons indicated above, on March 14, 2022 at 07:00 CET.

About Calliditas

Calliditas Therapeutics is a biopharmaceutical company based in Stockholm, Sweden focused on the identification, development and commercialization of new treatments in orphan indications, with an initial focus on kidney and liver diseases with significant unmet medical needs. Calliditas’ lead product, TARPEYO, has been approved by the FDA as the first and only treatment for IgA nephropathy (IgAN), indicated for the reduction of proteinuria in adults with primary IgAN at risk for rapid progression of disease, usually a UPCR of ≥ 1.5 g/gram. Calliditas has also submitted a Marketing Authorization Application (MA) to the European Medicines Agency (EMA) for this medicine. In addition, Calliditas has initiated a clinical trial in primary biliary cholangitis and also plans to initiate a trial in head and neck cancer with the NOX inhibitor product candidate, setanaxib. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market (ticker: CALT).

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding strategy, marketing efforts, business plans, regulatory submissions, clinical development plans and Calliditas direction. The words “may”, “will”, “could”, “would”, “should”, “expect”, “plan”, “anticipate”, “intend”, “believe”, ” estimates”, “predicts”, “project”, “potential”, “continue”, “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. All forward-looking statements contained in this press release are based on management’s current expectations and beliefs and are subject to a number of important risks, uncertainties and factors that may cause actual events or results to differ. differ materially from those expressed or implied by any forward-looking statement. forward-looking statements contained in this press release, including, without limitation, those relating to the business, operations of Calliditas, the continued FDA approval for TARPEYO, market acceptance of TARPEYO , clinical trials, supply chain, strategy, objectives and anticipated timelines, competition from other biopharmaceutical companies, and other risks identified in the section titled “Risk Factors” in the Calliditas reports filed with the Securities and Exchange Commission. Calliditas cautions you not to place undue reliance on forward-looking statements, which speak only as of the date they are made. Calliditas disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which such statements may be based, or which may affect the likelihood that actual results will differ from those statements. in forward-looking statements. All forward-looking statements contained in this press release represent the views of Calliditas only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/calliditas-therapeutics/r/expansion-of-everest-medicine-s-licence-agreement-to-include-south-korea,c3523939

The following files are available for download:

About Emilie Brandow

Check Also

South Korean won falls after Fed hike despite official warnings

A rating won by South Korea is seen in this illustrative photo from May 31, …